MedTrace Logo

Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

NCT07159243 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-09-08

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and PK parameter of HL-1186 tablet for diabetic peripheral neuropathic pain.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Sponsors & Collaborators

  • Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-10-31
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07159243 on ClinicalTrials.gov